-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, M9X8Pr6rIDnCHOxtvh33UiBi1hO1evbPVGuT9rFCV1KjkwcmpWD5gpbFFJKNocqb nOjxcM+5R0O8uhumqA0iXA== 0000950168-01-000651.txt : 20010402 0000950168-01-000651.hdr.sgml : 20010402 ACCESSION NUMBER: 0000950168-01-000651 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20000331 FILED AS OF DATE: 20010330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRIMERIS INC CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: SEC FILE NUMBER: 000-23155 FILM NUMBER: 1587931 BUSINESS ADDRESS: STREET 1: 4727 UNIVERSITY DR STE 100 CITY: DURHAM STATE: NC ZIP: 27707 BUSINESS PHONE: 9194196050 MAIL ADDRESS: STREET 1: 4727 UNIVERSITY DRIVE STE 100 CITY: DURHAM STATE: NC ZIP: 27707 10-Q/A 1 0001.txt AM. #1 TO FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A [x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2000 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ ------------------------------------------------------------------------- Commission File Number 0-23155 TRIMERIS, INC. (Exact name of registrant as specified in its charter) Delaware 56-1808663 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 4727 University Drive Durham, North Carolina 27707 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (919) 419-6050 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [x] Yes [ ] No The number of shares outstanding of the registrant's common stock as of May 12, 2000 was 15,649,259. Trimeris, Inc. Amendment No. 1 on Form 10-Q/A to the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2000. This Amendment No. 1 on Form 10-Q/A is being filed in order to restate the Company's financial statements as of, and for the quarterly periods ended, March 31, 1999 and 2000, and for the cumulative period from inception (January 7, 1993) to March 31, 2000, as described below. Under the terms of the Company's agreement with F. Hoffman -La Roche Ltd., or Roche, Roche made a cash payment in the amount of $10 million to the Company in July 1999, and in connection therewith the Company granted to Roche a warrant to purchase 362,000 shares of common stock at a purchase price of $20.72 per share. The Company also received reimbursement from Roche in 1999 for clinical trial drug inventory subsequently consumed. The Company is restating its financial statements as of, and for the quarterly period ended, March 31, 2000 and for the cumulative period from inception (January 7, 1993) to March 31, 2000, to: o reflect a reduction in revenue, and corresponding increase in stockholders' equity, equal to the fair value of this warrant at the grant date, o retroactively apply Staff Accounting Bulletin No. 101, resulting in amortization of the initial payment from Roche, net of the fair value of the warrants granted to Roche, over the research and development term of the Roche agreement, and o reflect a change in accounting for the reimbursement received from Roche in 1999 for clinical trial drug inventory subsequently consumed. This reimbursement is now being reflected as a reduction in research and development expense solely in the quarter ended September 30, 1999, and does not reduce research and development expense in any other quarter. The Company is also restating its financial statements as of, and for the quarterly periods ended March 31, 1999 and 2000 and for the cumulative period from inception (January 7, 1993) to March 31, 2000 to reflect a change in accounting for stock options issued to non-employees in accordance with Emerging Issues Task Force (EITF) 96-18, "Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services." As a result of this change in accounting, the measurement date used to calculate non-cash compensation expense incurred by the Company for stock options granted to non-employees is considered to be the date when all services are rendered. The items amended are as follows: Part I Item 1. Financial Statements Part I Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Part II Item 6. Exhibits and Reports on Form 8-K No other items have been amended. SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 1 on Form 10-Q/A to be signed on its behalf by the undersigned, thereunto duly authorized. Trimeris, Inc. ------------------- (Registrant) March 30, 2001 /s/ DANI P. BOLOGNESI -------------------------------- Dani P. Bolognesi, Ph.D. Chief Executive Officer and Chief Scientific Officer (principal executive officer) PART 1. FINANCIAL INFORMATION Item 1. Financial Statements TRIMERIS, INC. (A Development Stage Company) BALANCE SHEETS (in thousands, except par value)
December 31, March 31, 1999 2000 ---- ---- (restated) (unaudited) (restated) Assets Current assets: Cash and cash equivalents $ 37,023 $ 88,863 Short-term investments 10,775 16,447 Accounts receivable - Roche 144 3,014 Accounts receivable 24 12 Prepaid expenses 268 369 ----------- ---------- Total current assets 48,234 108,705 Property, furniture and equipment, net 2,585 2,576 ----------- ---------- Other assets: Patent costs, net 643 795 Equipment deposits 188 205 ----------- ---------- Total other assets 831 1,000 ----------- ---------- Total assets $ 51,650 $ 112,281 =========== ========== Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 6,159 $ 4,749 Current installments of capital lease obligations 717 809 Accrued compensation 1,028 799 Deferred revenue - Roche -- 840 Accrued expenses 3,474 3,495 ------------- ---------- Total current liabilities 11,378 10,692 Obligations under capital leases, excluding current installments 1,206 1,270 Deferred revenue - Roche -- 3,130 ----------- ---------- Total liabilities 12,584 15,092 ----------- ---------- Commitments and contingencies Stockholders' equity: Series A, B, C, and D preferred stock at $.001 par value per share, 10,000 shares authorized, zero shares issued and outstanding at December 31, 1999 and March 31, 2000 (unaudited) -- -- Common Stock at $.001 par value per share, 30,000 shares authorized, 13,765 and 15,648 shares issued and outstanding at December 31, 1999 and March 31, 2000 (unaudited) 14 16 Additional paid-in capital 112,908 187,248 Deficit accumulated during the development stage (71,298) (87,845) Deferred compensation (2,453) (2,189) Notes receivable from stockholders (105) (41) ------------ ----------- Net stockholders' equity 39,066 97,189 ----------- ---------- Total liabilities and stockholders' equity $ 51,650 $ 112,281 ============ ==========
See accompanying notes to financial statements. 1 TRIMERIS, INC. (A Development Stage Company) STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited)
Cumulative Three Months from Inception Ended March 31, (January 7, 1993) ------------------ to March 31, 1999 2000 2000 ---- ---- ---- (restated) (restated) (restated) Revenue $ 81 $ 210 $ 5,844 -------- -------- -------- Operating expenses: Research and development: Non-cash compensation 246 3,504 6,692 Other research and development expense 3,871 5,042 60,748 -------- -------- -------- Total research and development expense 4,117 8,546 67,440 -------- -------- -------- General and administrative: Non-cash compensation 170 3,606 6,925 Other general and administrative expense 1,583 1,637 19,355 -------- -------- -------- Total general and administrative expense 1,753 5,243 26,280 -------- -------- -------- Total operating expenses 5,870 13,789 93,720 -------- -------- -------- Operating loss (5,789) (13,579) (87,876) -------- -------- -------- Other income (expense): Interest income 231 1,266 5,456 Interest expense (42) (54) (1,245) -------- -------- -------- Total other income (expense) 189 1,212 4,211 -------- -------- -------- Net loss before cumulative effect of change in accounting principle $ (5,600) $(12,367) $(83,665) Cumulative effect of change in accounting principle -- (4,180) (4,180) -------- -------- -------- Net loss $ (5,600) $(16,547) $(87,845) ======== ======== ======== Basic net loss per share: Before cumulative effect of accounting change $ (0.52) $ (0.83) Accounting change -- (0.28) -------- -------- Basic net loss per share $ (0.52) $ (1.11) ======== ======== Weighted average shares used in per share computations 10,677 14,942 ======== ========
See accompanying notes to financial statements. 2 TRIMERIS, INC. (A Development Stage Company) STATEMENTS OF CASH FLOWS (in thousands) (unaudited) (restated)
Cumulative Three Months Ended From Inception March 31, (January 7, 1993) --------------------- to March 31, 1999 2000 2000 ---- ---- ---- Cash flows from operating activities: Net loss $(5,600) $ (16,547) $(87,845) Adjustments to reconcile net loss to net cash used by operating activities: Depreciation 183 340 3,924 Other amortization 5 - 83 Amortization of deferred revenue - Roche -- (210) (210) Non-cash compensation expense 416 7,110 13,617 401(K) plan stock match - - 528 Provision for equipment held for resale - - 61 Stock issued for consulting services - - 5 Stock issued to repay interest on notes to stockholders - - 195 Debt issued for research and development - - 194 Cumulative effect of change in accounting principle - 4,180 4,180 Loss on disposal of property and equipment - - 16 Changes in operating assets and liabilities: Accounts receivable and loans to employees 22 12 (12) Accounts receivable - Roche - (2,870) (3,014) Prepaid expenses (12) (101) (369) Other assets (5) (17) (205) Accounts payable (789) (1,410) 4,749 Accrued compensation 327 (229) 799 Accrued expenses (354) 21 3,405 -------- --------- -------- Net cash used by operating activities (5,807) (9,721) (59,899) -------- ---------- --------- Cash flows from investing activities: Sales (purchases) of short-term investments (895) (5,672) (16,447) Purchases of property and equipment (306) - (1,504) Equipment held for resale - - (61) Organization costs - - (8) Patent costs (7) (152) (816) -------- ---------- --------- Net cash used by investing activities (1,208) (5,824) (18,836) -------- ---------- --------- Cash flows from financing activities: Proceeds from issuance of notes payable - - 6,150 Lease costs - - (13) Principal payments under capital lease obligations (127) (175) (2,933) Proceeds from issuance of Common Stock - - 31 Proceeds from issuance of Preferred Stock - - 23,896 Proceeds from stock offerings, net - 66,570 132,459 Proceeds from exercise of stock options 29 926 2,102 Proceeds from employee stock purchase plan exercise - - 475 Repayment of notes receivable from stockholders 24 64 227 Warrant issuance -- -- 5,400 Stock issuance costs - - (196) ------- --------- --------- Net cash provided (used) by financing activities (74) 67,385 167,598 -------- --------- -------- Net increase (decrease) in cash and cash equivalents (7,089) 51,840 88,863 Cash and cash equivalents, beginning of period 16,920 37,023 - ------- --------- -------- Cash and cash equivalents, end of period $ 9,831 $ 88,863 $ 88,863 ======= ========= ========
See accompanying notes to financial statements. 3 TRIMERIS, INC. (A Development Stage Company) NOTES TO FINANCIAL STATEMENTS (unaudited) 1. BASIS OF PRESENTATION Trimeris, Inc. (the "Company") was incorporated on January 7, 1993 to discover and develop novel therapeutic agents that block viral infection by inhibiting viral fusion with host cells. These financial statements have been prepared in accordance with Statement of Financial Accounting Standards No. 7, "Accounting and Reporting by Development Stage Enterprises," to recognize the fact that the Company is devoting substantially all of its efforts to establishing a new business and planned principal operations have not commenced. The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles and applicable Securities and Exchange Commission regulations for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the Securities and Exchange Commission rules and regulations. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of financial position and results of operations have been made. Operating results for interim periods are not necessarily indicative of results which may be expected for a full year. The information included in this Form 10-Q should be read in conjunction with the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections and the 1999 financial statements and notes thereto included in the Company's 1999 Form 10-K/A filed with the Securities and Exchange Commission on March 30, 2001. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The financial statements for the three months ended March 31, 2000 have been restated to reflect a reduction in revenue with a corresponding increase in additional paid-in capital for the $5.4 million fair value of a warrant issued to Roche in July 1999, and a change in accounting for reimbursement received from Roche in 1999 for clinical trial drug inventory subsequently consumed. The financial statements for the three months ended March 31, 1999 and 2000 have also been restated to reflect a change in accounting for stock options issued to non-employees in accordance with Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" ("SFAS No. 123") and Emerging Issues Task Force (EITF) Issue No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services. In addition, Staff Accounting Bulletin No. 101 has been applied retroactively to January 1, 2000 as the cumulative effect of a change in accounting principle resulting in deferral and amortization of the initial $10 million payment from Roche, net of the $5.4 million fair value of the warrant, over the research and development term of the Roche agreement. The cumulative period from inception (January 7, 1993) to March 31, 2000 has also been restated for these items. The net impact of the restatements described above increased net loss for the three months ended March 31, 1999 by $233,000 or $0.02 per share, increased net loss for the three months ended March 31, 2000 by $7.1 million or $0.47 per share, and increased the cumulative net loss from inception (January 7, 1993) to March 31, 2000 by $15.4 million. In addition, the cumulative effect of the change in accounting principle, net of current period amortization, increased net loss by $3.9 million or $0.27 per share for the three months ended March 31, 2000. 4 2. BASIC NET INCOME (LOSS) PER SHARE In accordance with SFAS No. 128, "Earnings Per Share" ("SFAS No. 128"), basic loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period after certain adjustments described below. Diluted net income per common share reflects the maximum dilutive effect of common stock issuable upon exercise of stock options, stock warrants, and conversion of preferred stock. Diluted net loss per common share is not shown, as common equivalent shares from stock options, and stock warrants, would have an antidilutive effect. At March 31, 2000 there were 1,707,000 options to purchase common stock outstanding and a warrant to purchase 362,000 shares of common stock outstanding. 3. STATEMENTS OF CASH FLOWS Interest of approximately $42,000 and $54,000 was paid during the three months ended March 31, 1999 and 2000, respectively. Capital leases of $0 and $331,000 were incurred for the three months ended March 31, 1999 and 2000, respectively for the purchase of new furniture and equipment. 4. PUBLIC OFFERINGS OF STOCK In October 1997, the Company closed its initial public offering of common stock at $12 per share. The net proceeds of the offering, including the proceeds received in connection with the exercise of the Underwriters' over-allotment option which closed in November 1997, were approximately $34.5 million after deducting applicable issuance costs and expenses. In connection with the public offering, all the outstanding preferred stock was converted into 6,261,615 shares of the Company's common stock. In June 1999, the Company closed a public offering of common stock at $11.75 per share. The net proceeds of the offering, including the proceeds received in connection with the exercise of the Underwriters' over-allotment option, were approximately $31.4 million after deducting applicable issuance costs and expenses. In February 2000, the Company closed a private placement of 1.75 million shares of common stock at $40.50 per share. The net proceeds of the offering were approximately $66.6 million after deducting applicable issuance costs and expenses. 5. STOCK SPLIT Effective July 11, 1997, the Company declared a one for eight and one-half reverse stock split for common stockholders. This stock split has been retroactively applied and all periods presented have been restated. 6. ROCHE COLLABORATION In July 1999, the Company announced an agreement with F. Hoffmann-La Roche Ltd to develop and market T20 and T1249 worldwide. In the United States and Canada, the Company and Roche will share equally development expenses and profits for the two fusion inhibitors. Outside of these two countries, Roche will fund all development costs and pay the Company royalties on net sales of these products. Roche made an initial cash payment to the Company of $10 million and will provide up to an additional $58 million in cash and funding upon achievement of developmental, regulatory and commercial milestones. In accordance with Staff Accounting Bulletin No. 101, the initial cash payment, net of the $5.4 million fair value of the warrant granted to Roche, is being amortized into revenue over the research and development term of the Roche agreement. 5 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This discussion of our financial condition and the results of operations should be read together with the financial statements and notes contained elsewhere in this Form 10-Q. Certain statements in this section and other sections are forward-looking. While we believe these statements are accurate, our business is dependent on many factors, some of which are discussed in the "Risk Factors" and "Business" sections of our 1999 Form 10-K filed with the Securities and Exchange Commission on March 29, 2000. These factors include, but are not limited to: that we are an early stage company with an uncertain future; that we have never made money and expect our losses to continue; that we will need to raise additional funds in the near future; that our quarterly operating results are subject to fluctuations and you should not rely on them as an indication of our future results; that we are heavily dependent on our lead product candidate, T20; that our success in commercializing T20 and T1249 is dependent on our relationship with Roche; that we face many uncertainties relating to our human clinical trial results and clinical trial strategy; that HIV may develop resistance to our drug candidates; that we have no experience manufacturing pharmaceutical products; that we face risks associated with manufacturing T20 and T1249; that our business is based on novel technology and is highly risky and uncertain; that we are dependent on third-party contract research organizations; that we have no sales, marketing or distribution capabilities; that our stock price is highly volatile; that we depend on collaborations and licenses with others; that there is uncertainty relating to third-party reimbursement and health care reform measures which could limit the amount we will be able to charge for our products; that there is uncertainty regarding patents and proprietary rights; that we are subject to extensive government regulation; that our products may not receive regulatory approval; that we face intense competition; that we use hazardous materials; that we are exposed to product liability risks; that we depend upon certain key personnel and face risks relating to our ability to attract and retain key personnel; that future sales of common stock by our existing stockholders could adversely affect our stock price; that we have implemented certain anti-takeover provisions; and that our actual results could differ materially from those anticipated in our forward-looking statements. Many of these factors are beyond our control and any of these and other factors could cause actual results to differ materially from the forward-looking statements made in this 10-Q. The results of our previous clinical trials are not necessarily indicative of the results of future clinical trials. We undertake no obligation to release publicly the results of any revisions to the statements contained in this Form 10-Q to reflect events or circumstances that occur subsequent to the date hereof. Overview We began our operations in January 1993 and are a development stage company. Accordingly, we have a limited operating history. Since our inception, substantially all of our resources have been dedicated to: o the development, patenting, preclinical testing and clinical trials of T20, o the development of a manufacturing process for T20, o production of drug material for future clinical trials, and o research and development and preclinical testing of other potential product candidates. We have lost money since inception and, as of March 31, 2000, had an accumulated deficit of approximately $87.8 million. We have received revenue only from federal small business innovative research grants, otherwise known as SBIR grants, an investigative contract, and an initial collaboration payment from Roche, and have not generated any revenue from product sales or royalties. We may never generate any revenue from product sales or royalties. 6 Development of current and future drug candidates will require significant additional, time-consuming and costly research and development, preclinical testing and extensive clinical trials prior to submission of any regulatory application for commercial use. We expect to incur substantial losses for the foreseeable future and expect losses to increase as our research and development, preclinical testing, drug production and clinical trial efforts expand. The amount and timing of our operating expenses will depend on many factors, including: o the status of our research and development activities, o product candidate discovery and development efforts, including preclinical testing and clinical trials, o the timing of regulatory actions, o the costs involved in preparing, filing, prosecuting, maintaining, protecting and enforcing patent claims and other proprietary rights, o our ability to work with Roche to manufacture, develop, sell, market and distribute T20 and T1249, o technological and other changes in the competitive landscape, o changes in our existing research and development relationships and strategic alliances, o evaluation of the commercial viability of potential product candidates, and o other factors, many of which are outside of our control. As a result, we believe that period-to-period comparisons of our financial results in the future are not necessarily meaningful. The past results of operations and results of previous clinical trials should not be relied on as an indication of future performance. If we fail to meet the clinical and financial expectations of securities analysts and investors, it could have a material adverse effect on the market price of our common stock. Our ability to achieve profitability will depend, in part, on our own or our collaborative partner's ability to successfully develop and obtain regulatory approval for T20 or T1249 and other product candidates, and our ability to develop the capacity, either internally or through relationships with third parties, to manufacture, sell, market and distribute approved products, if any. We may never generate significant revenues or achieve profitable operations. 7 Results of Operations COMPARISON OF THREE MONTHS ENDED MARCH 31, 1999 AND 2000 REVENUE. Total revenue increased from $81,000 for the three months ended March 31, 1999 to $210,000 for the three months ended March 31, 2000. Total revenue for the three months ended March 31, 1999 was entirely derived from SBIR grants. Total revenue for the three months ended March 31, 2000 represents the amortization of the $10 million initial collaboration payment from Roche, net of the $5.4 million value assigned to the warrant issued to Roche, over the research and development term of the agreement. RESEARCH AND DEVELOPMENT EXPENSES. Total net research and development expenses were $4.1 million and $8.5 million for the three months ended March 31, 1999 and 2000, respectively. Gross research and development expenses increased during the three months ended March 31, 2000 because we: o continued three Phase II clinical trials for T20, o initiated a fourth Phase II clinical trial for T20, o continued a Phase I clinical trial for T1249, o continued manufacturing process development and purchase of drug material from third party manufacturers to supply future clinical trials, and o increased the number of our personnel to support these activities. Non-cash compensation expense increased from $246,000 for the three months ended March 31, 1999 to $3.5 million for the three months ended March 31, 2000 due to the effect that increases in the market value of our stock during the quarter ended March 31, 2000 had on the calculation of this expense under EITF 96-18 for stock options granted to non-employees. Total research and development expenses include gross research and development expenses less Roche's share of development costs for T-20 and T-1249. Under our collaboration agreement we and Roche shared the development costs for T-20 and T-1249 incurred during the three months ended March 31, 2000. Total research personnel were 41 and 55 at March 31, 1999 and 2000, respectively. We expect research and development expenses, net of the reimbursements for T20 and T1249 development costs from Roche, to increase substantially in the future due to: o continued preclinical research and testing of product candidates, o expanded clinical trials for T20, T1249 and other product candidates, o the manufacture of drug material for these trials, and o increased number of personnel to support these activities. GENERAL AND ADMINISTRATIVE EXPENSES. Total general and administrative expenses were $1.8 million and $5.2 million for the three months ended March 31, 1999 and 2000, respectively. During 1999 we made a non-recurring accrual of severance costs for our former chief executive officer. Total expenses increased during the three months ended March 31, 2000 because in 2000 we: o initiated several market research studies which are shared equally with Roche, o expensed deferred compensation relating to stock options granted to consultants during 1999, o added personnel to support our growth, and o incurred professional fees to support our growth. 8 Non-cash compensation expense increased from $170,000 for the three months ended March 31, 1999 to $3.6 million for the three months ended March 31, 2000 due to the effect that increases in the market value of our stock during the quarter ended March 31, 2000 had on the calculation of this expense under EITF 96-18 for stock options granted to non-employees. We expect administrative expenses to increase in the future to support the anticipated expansion of product development activities. OTHER INCOME (EXPENSE). Other income (expense) consists of interest income and expense. Total other income was $189,000 and $1.2 million for the three months ended March 31, 1999 and 2000, respectively. The increase was due to increased interest income because of higher cash and investment balances during the three months ended March 31, 2000 due to our stock offerings closed in June 1999 and February 2000. Liquidity and Capital Resources Since inception, we have financed our operations primarily through the private placement of equity securities, the issuance of notes to stockholders, equipment lease financing, an initial public offering of common stock in October 1997, a public offering of common stock in June 1999, and a private placement of common stock in February 2000. Net cash used by operating activities was $5.8 million and $9.7 million for the three months ended March 31, 1999 and 2000, respectively. The cash used by operating activities was used primarily to fund research and development relating to T20, T1249, and other product candidates, and increased for the three months ended March 31, 2000 because of increased research and development activities. Cash used by investing activities was $1.2 million and $5.8 million for the three months ended March 31, 1999 and 2000, respectively. The increase for the three months ended March 31, 2000 was due to the purchase of short-term investments as a result of our public offering of common stock in February 2000. As of March 31, 2000, we had $105.3 million in cash and cash equivalents and short-term-investments, compared to $47.8 million as of December 31, 1999. The increase is primarily a result of the closing of a private placement of common stock in February 2000, which resulted in net proceeds of approximately $66.6 million, less cash used by operating activities. We have experienced negative cash flows from operations since our inception and do not anticipate generating sufficient positive cash flows to fund our operations in the foreseeable future. Although we expect to receive reimbursement for 50% of the development costs for T20 and T1249 from Roche, we have expended, and expect to continue to expend in the future, substantial funds to pursue our product candidate and compound discovery and development efforts, including: o expenditures for clinical trials of T20, T1249 and other product candidates, o research and development and preclinical testing of other product candidates, o manufacture of drug material, and o the development of our proprietary technology platform. As of March 31, 2000, we had commitments of approximately $29.0 million to purchase product candidate materials and fund various clinical studies over the next fifteen months. Substantially all of these expenditures will be shared equally by Roche under our collaborative agreement. Under this collaborative agreement, we are obligated to share equally the future development expenses for T20 and T1249 for the United States and Canada. We also expect to have capital expenditures of approximately $2.5 million during the remainder of 2000. Our share of these expenditures may be financed with capital or operating leases, debt or working capital. We expect that our existing capital resources, together with the interest earned thereon, will be adequate to fund our capital requirements through 2000. We believe that substantial additional funds will be required after 2000. 9 If adequate funds are not available, we will be required to delay, scale-back or eliminate certain preclinical testing, clinical trials and research and development programs, including our collaborative efforts with Roche. In addition, we will be required to obtain additional funds, which may be raised through equity or debt financings. If we raise funds by selling equity, our stockholders' interest may be diluted. Any debt financings may contain restrictive terms that limit our operating flexibility. Additionally or alternatively, we may have to attempt to obtain funds through arrangements with new or existing collaborative partners. These partners may require us to relinquish rights to our technologies or product candidates or to reduce our share of potential profits. This could have a material adverse effect on our business, financial condition or results of operations. Our future capital requirements and the adequacy of available funds will depend on many factors, including the availability of funds from Roche under our collaboration agreement, the results of clinical trials relating to T20 and T1249, the progress and scope of our product development programs, the magnitude of these programs, the results of preclinical testing and clinical trials, the need for additional facilities based on the results of these clinical trials and other product development programs, changes in the focus and direction of our product development programs, the costs involved in preparing, filing, processing, maintaining, protecting and enforcing patent claims and other intellectual property rights, competitive factors and technological advances, the cost, timing and outcome of regulatory reviews, changes in the requirements of the FDA, administrative and legal expenses, evaluation of the commercial viability of potential product candidates and compounds, the establishment of capacity, either internally or through relationships with third parties, for manufacturing, sales, marketing and distribution functions, and other factors, many of which are outside of our control. Factors That May Affect Future Results and Financial Condition Clinical Development The following discussion highlights certain aspects of our on-going and planned clinical development programs. The results of our previous clinical trials are not necessarily indicative of the results of future clinical trials. T20 We are developing T20, our first drug candidate for HIV fusion inhibition, which has been granted fast track designation by the FDA. T20 is currently in Phase II clinical trials. Ongoing T20 Clinical Trials Phase II -- T20-205. T20-205 is a Phase II trial initiated in March 1999 in which T20 was given in combination with oral anti-HIV drugs to 71 HIV-1 infected adults who had received T20 during earlier trials. Fifty mg of T20 was given twice daily via subcutaneous injection. Combinations of the oral anti-HIV drugs were individualized to each patient and were chosen based on genotypic analysis evaluating patients' resistance to anti-HIV medications. In January 2000, we extended T20-205 beyond the initial 48 week duration because patients in the trial appeared to continue receiving clinical benefit. Patients will continue to receive T-20 therapy at their election, as long as they show clinical benefit. Additional data from this trial is expected during 2000. Phase II -- T20-204. In November 1999, in collaboration with the Division of AIDS of the National Institute for Allergy and Infectious Diseases, or NIAID, we initiated a clinical trial to evaluate the safety and pharmacokinetics of T20 in children living with HIV infection. The trial will be managed by the Pediatric AIDS Clinical Trial Group, or PACTG, and has been designated as a fast-track study within the PACTG system. The study is designed to investigate the safety, tolerability and pharmacokinetics of T20 in pediatric patients. The trial is conducted in two parts and will enroll up to twelve pediatric patients ages 3 to 12. The first part examines safety parameters to establish a well-tolerated pediatric dose that provides target concentrations of T-20 in the blood. The second part evaluates the safety and tolerability of T20 in combination with other anti-HIV drugs over a 24-week period. In this study, T20 is administered via subcutaneous injections twice daily in conjunction with other oral anti-HIV drugs. 10 Phase II -- T20-206. In June 1999, we initiated T20-206, a Phase II clinical trial for T20 that will assess the antiviral activity and long-term safety of T-20 when used in combination with other anti-HIV drugs. T20-206 evaluates four groups of patients over a one-year period with planned interim analyses. Three different doses of T20 will be combined with a background regimen of amprenavir, efavirenz, ritonavir and abacavir. The control group will receive the background regimen without T20. T20-206 will enroll approximately 68 HIV-infected individuals at several sites in the United States. At entry in the trial, all enrolled patients will have prior exposure to nucleoside reverse transcriptase inhibitors and protease inhibitors, but no prior exposure to non-nucleoside reverse transcriptase inhibitors. The trial is fully enrolled and data from an interim analysis of this trial is expected during 2000. Phase II - T20-208. In March 2000, we initiated T20-208, a Phase II clinical trial for T20 that will evaluate alternative formulations of T20, which could lead to a simpler dosing regimen. The trial is designed to enroll approximately 60 patients in the United States, and will evaluate two formulations of T20 compared to the formulation presently used in other ongoing clinical trials. All three formulations will be given as twice daily subcutaneous injections in combination with oral anti-HIV agents selected for each patient on an individualized basis. Future T-20 Clinical Trials Throughout the remainder of 2000, we expect to initiate additional Phase II trials. We expect to begin a pivotal trial during 2000. Pivotal Trial. Based on the results of the Phase II trials, we intend to begin a pivotal trial during 2000 in a larger population of HIV-infected patients who are either resistant to, or intolerant of, currently-approved anti-HIV drugs. Historically, pivotal trials of this type involving anti-HIV drugs have included approximately 300 to 400 patients and have taken approximately 18 months to complete. T1249 We are also developing T1249, our second drug candidate for HIV fusion inhibition, which has been granted fast track designation by the FDA. T1249 is currently in a Phase I clinical trial. Phase I - T1249-101 In July 1999, we initiated T1249-101, a Phase I clinical trial designed to assess the safety and pharmacokinetics of T1249. Three different daily doses of T1249 will be administered as monotherapy for 14 days to HIV-infected adults by once or twice daily subcutaneous injection. T1249-101 will enroll approximately 60 HIV-infected individuals at several sites in the United States. At entry, these patients will have received no other anti-HIV drugs for at least two weeks prior to entering the study. This trial is fully enrolled and ongoing, and we expect data from this trial to be available during 2000. Risk Factors Our business is subject to certain risks and uncertainties. Please read the "Risk Factors" and "Business" sections of our 1999 Form 10-K filed with the Securities and Exchange Commission on March 29, 2000, which highlight some of these risks. If any of these risks materialize, our business, financial condition and results of operations could be materially adversely affected. 11 PART II. OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K (a) Exhibits The exhibits filed as part of this Quarterly Report on Form 10-Q are listed on the Exhibit Index immediately preceding such exhibits and such list is incorporated herein by reference. (b) Reports on Form 8-K We filed a report on Form 8-K on January 28, 2000 under Item 5 describing our plans to complete a private placement of our common stock to new and current shareholders in order to raise net proceeds of up to approximately $65 million. We filed a report on Form 8-K on February 4, 2000 under Item 5 announcing the closing of a private placement of 1,750,000 shares of common stock to new and current shareholders at a price per share of $40.50. We filed a report on Form 8-K on April 3, 2000 under Item 5 describing certain changes in management. On April 3, 2000, Dr. M. Nixon Ellis was appointed Executive Vice President and Chief Business Officer, and Mr. Robert Bonczek was appointed Chief Financial Officer. 12 EXHIBIT INDEX Number Description - ------ ----------- 10.1* Employment Agreement between Trimeris, Inc. and M. Nixon Ellis dated March 31, 2000 11.1 Computations of Basic Loss Per Share 27.1 Financial Data Schedule * Incorporated by reference to Trimeris' Quarterly Report on Form 10-Q for the quarter ended March 31, 2000 EX-11 2 0002.txt COMPUTATIONS OF BASIC NET LOSS PER SHARE Exhibit 11.1 Computations of Basic Loss Per Share. TRIMERIS, INC. STATEMENTS RE: COMPUTATIONS OF BASIC LOSS PER SHARE (in thousands, except per share data) Three Months Ended March 31, --------------- 1999 2000 ---- ---- Common shares outstanding (weighted average) 10,677 14,942 ======== ========= Net loss before accounting change $ (5,600) $ (12,367) Accounting change -- (4,180) -------- ---------- Net loss (5,600) $ (16,547) ========= ========== Basic net loss per share: Before cumulative effect of accounting change $ (0.52) $ (0.83) Accounting change -- (0.28) --------- --------- Basic net loss per share $ (0.52) $ (1.11) ======== ========== EX-27 3 0003.txt FDS
5 3-MOS DEC-31-2000 MAR-20-2000 88,863 16,447 3,026 0 0 108,705 6,405 3,829 112,281 10,692 0 0 0 16 97,173 112,281 0 0 0 0 13,789 0 54 (12,367) 0 (12,367) 0 0 (4,180) (16,547) (1.11) (1.11)
-----END PRIVACY-ENHANCED MESSAGE-----